期刊文献+

Telomerase-specific oncolytic virotherapy for humanhepatocellular carcinoma 被引量:1

Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma
下载PDF
导出
摘要 AIM: To evaluate the therapeutic efficiency of replicative adenovirus CNHK300 targeted in telomerase-positive hepatoceUular carcinoma.METHODS: CNHK300, ONYX-015 (55 kDa protein deleted adenovirus) and wtAd5 (wild type adenovirus 5) were compared, and virus proliferation assay, cell viability assay, Western blot and fluorescence microscopy were used to evaluate the proliferation and cytolysis selectivity of CNHK300.RESULTS: The replicative multiples in Hep3B and HepG Ⅰ after 48 Ⅱ of CNHK300 proliferation were 40625 and 65326 fold, respectively, similar to that of wtAd5.. However, CNHK300 exhibited attenuated replicative ability in normal fibroblast cell line BJ. CNHK300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection (MOI), but could not affect growth of normal cells even at a high MOI.CONCLUSION: CNHK300 is a cancer-selective replication-competent adenovirus which can cause oncolysis of liver cancer cells as well as wtAd5 (wild type adenovirus 5), but had severely attenuated replicative and cytolytic ability in normal cells. This novel strategy of cancer treatment offers a promising treatment platform. AIM:To evaluate the therapeutic efficiency of replicative adenovirus CNHK300 targeted in telomerase-positive hepatocellular carcinoma. METHODS:CNHK300, ONYX-015 (55 kDa protein deleted adenovirus) and wtAd5 (wild type adenovirus 5) were compared, and virus proliferation assay, cell viability assay, Western blot and fluorescence microscopy were used to evaluate the proliferation and cytolysis selectivity of CNHK300. RESULTS:The replicative multiples in Hep3B and HepG Ⅱ after 48 h of CNHK300 proliferation were 40 625 and 65 326 fold, respectively, similar to that of wtAd5.. However, CNHK300 exhibited attenuated replicative ability in normal fibroblast cell line BJ. CNHK300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection (MOI), but could not affect growth of normal cells even at a high MOI. CONCLUSION:CNHK300 is a cancer-selective replication-competent adenovirus which can cause oncolysis of liver cancer cells as well as wtAd5 (wild type adenovirus 5), but had severely attenuated replicative and cytolytic ability in normal cells. This novel strategy of cancer treatment offers a promising treatment platform.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第8期1274-1279,共6页 世界胃肠病学杂志(英文版)
基金 International Cooperative Key Project of the National Natural Science Foundation of China, No. 30120160824 the State 863 High Technology R&D Project of China, No. 2001AA217031
关键词 Gene therapy Virus therapy Replicative adenovirus Heptocellular carcinoma 肝细胞癌 基因治疗 病毒治疗 腺病毒
  • 相关文献

参考文献30

  • 1[1]Russell WC.Update on adenovirus and its vectors.J Gen Virol 2000; 81:2573-2604
  • 2[2]Vile RG,Russell SJ,Lemoine NR.Cancer gene therapy:hard lessons and new courses.Gene Ther 2000; 7:2-8
  • 3[3]Ring CJ.Cytolytic viruses as potential anti-cancer agents.J Gen Virol 2002; 83:491-502
  • 4[4]Kasuya H,Nishiyama Y,Nomoto S,Goshima F,Takeda S,Watanabe I,Nomura N,Shikano T,Fujii T,Kanazumi N,Nakao A.Suitability of a US3-inactivated HSV mutant (LIBR1)as an oncolytic virus for pancreatic cancer therapy.Cancer Gene Ther 2007; 14:533-542
  • 5[5]Wollmann G,Robek MD,van den Pol AN.Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.J Virol 2007; 81:1479-1491
  • 6[6]Lamfers ML,Fulci G,Gianni D,Tang Y,Kurozumi K,Kaur B,Moeniralm S,Saeki Y,Carette JE,Weissleder R,Vandertop WP,van Beusechem VW,Dirven CM,Chiocca EA.Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Mol Ther 2006; 14:779-788
  • 7[7]Kurihara T,Brough DE,Kovesdi I,Kufe DW.Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.J Clin Invest 2000; 106:763-771
  • 8[8]Dilley J,Reddy S,Ko D,Nguyen N,Rojas G,Working P,Yu DC.Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.Cancer Gene Ther 2005; 12:715-722
  • 9[9]Small EJ,Carducci MA,Burke JM,Rodriguez R,Fong L,van Ummersen L,Yu DC,Aimi J,Ando D,Working P,Kirn D,Wilding G.A phase I trial of intravenous CG7870,a replication-selective,prostate-specific antigen-targeted oncolytic adenovirus,for the treatment of hormone-refractory,metastatic prostate cancer.Mol Ther 2006; 14:107-117
  • 10[10]Ren XW,Liang M,Meng X,Ye X,Ma H,Zhao Y,Guo J,Cai N,Chen HZ,Ye SL,Hu F.A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.Cancer Gene Ther 2006;13:159-168

同被引文献2

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部